177 related articles for article (PubMed ID: 11091154)
1. Prospects for phase III-IV HPV vaccination trials in the Nordic countries and in Estonia.
Lehtinen M; Kibur M; Luostarinen T; Anttila A; Pukkala E
J Clin Virol; 2000 Oct; 19(1-2):113-22. PubMed ID: 11091154
[TBL] [Abstract][Full Text] [Related]
2. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
3. Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: Cancer registry-based follow-up.
Rana MM; Huhtala H; Apter D; Eriksson T; Luostarinen T; Natunen K; Paavonen J; Pukkala E; Lehtinen M
Int J Cancer; 2013 Jun; 132(12):2833-8. PubMed ID: 23180157
[TBL] [Abstract][Full Text] [Related]
4. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy.
Lehtinen M; Idänpään-Heikkilä I; Lunnas T; Palmroth J; Barr E; Cacciatore R; Isaksson R; Kekki M; Koskela P; Kosunen E; Kuortti M; Lahti L; Liljamo T; Luostarinen T; Apter D; Pukkala E; Paavonen J
Int J STD AIDS; 2006 Apr; 17(4):237-46. PubMed ID: 16595046
[TBL] [Abstract][Full Text] [Related]
5. Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination.
Kibur M; af Geijerstamm V; Pukkala E; Koskela P; Luostarinen T; Paavonen J; Schiller J; Wang Z; Dillner J; Lehtinen M
Sex Transm Infect; 2000 Feb; 76(1):13-7. PubMed ID: 10817062
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
Barnabas RV; Laukkanen P; Koskela P; Kontula O; Lehtinen M; Garnett GP
PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
[TBL] [Abstract][Full Text] [Related]
7. [Cervical cancer prevention: the impact of HPV vaccination].
Monsonégo J
Gynecol Obstet Fertil; 2006 Mar; 34(3):189-201. PubMed ID: 16529969
[TBL] [Abstract][Full Text] [Related]
8. [Human papillomavirus: a vaccine against cervical carcinoma uterine].
Franceschi S
Epidemiol Prev; 2002; 26(3):140-4. PubMed ID: 12197051
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of preventive human papillomavirus vaccination.
Lehtinen M; Paavonen J
Int J STD AIDS; 2003 Dec; 14(12):787-92. PubMed ID: 14678583
[TBL] [Abstract][Full Text] [Related]
10. Strategies for HPV prevention.
Plummer M; Franceschi S
Virus Res; 2002 Nov; 89(2):285-93. PubMed ID: 12445668
[TBL] [Abstract][Full Text] [Related]
11. The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management.
Brinkman JA; Caffrey AS; Muderspach LI; Roman LD; Kast WM
Eur J Gynaecol Oncol; 2005; 26(2):129-42. PubMed ID: 15857016
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine.
Goldie SJ; Grima D; Kohli M; Wright TC; Weinstein M; Franco E
Int J Cancer; 2003 Oct; 106(6):896-904. PubMed ID: 12918067
[TBL] [Abstract][Full Text] [Related]
13. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
14. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.
Goldie SJ; Kohli M; Grima D; Weinstein MC; Wright TC; Bosch FX; Franco E
J Natl Cancer Inst; 2004 Apr; 96(8):604-15. PubMed ID: 15100338
[TBL] [Abstract][Full Text] [Related]
15. A controlled trial of a human papillomavirus type 16 vaccine.
Koutsky LA; Ault KA; Wheeler CM; Brown DR; Barr E; Alvarez FB; Chiacchierini LM; Jansen KU;
N Engl J Med; 2002 Nov; 347(21):1645-51. PubMed ID: 12444178
[TBL] [Abstract][Full Text] [Related]
16. Eligibility and willingness of young Icelandic women to participate in a HPV vaccination trial.
Gudmundsdóttir T; Tryggvadóttir L; Allende M; Mast TC; Briem H; Sigurdsson K
Acta Obstet Gynecol Scand; 2003 Apr; 82(4):345-50. PubMed ID: 12716319
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs.
Murillo R; Ordóñez-Reyes C
Int J Gynecol Cancer; 2019 Oct; 29(8):1317-1326. PubMed ID: 31455660
[TBL] [Abstract][Full Text] [Related]
18. [HPV vaccination--a possibility for prevention of cervical cancer].
Paavonen J
Duodecim; 2002; 118(21):2159-60. PubMed ID: 12486951
[No Abstract] [Full Text] [Related]
19. [Vaccination against human papillomavirus for the prevention of cervical cancer].
Quint WG; ter Harmsel WA; van Doorn LJ
Ned Tijdschr Geneeskd; 2006 Jun; 150(25):1380-4. PubMed ID: 16841585
[TBL] [Abstract][Full Text] [Related]
20. [Can human papillomavirus testing and vaccination prevent cervical cancer?].
Lie AK; Bjørge T; Helland A; Hagen B; Skjeldestad FE; Hagmar B; Thoresen S
Tidsskr Nor Laegeforen; 2001 Oct; 121(25):2947-51. PubMed ID: 11715778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
